^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RAD51 overexpression

    i
    Other names: RAD51, RAD51 Recombinase, BRCA1/BRCA2-Containing Complex Subunit 5, DNA Repair Protein RAD51 Homolog 1, RAD51 Homolog A, HRAD51, RAD51A, RECA, RAD51 Homolog (RecA Homolog, E. Coli) (S. Cerevisiae), RAD51 (S. Cerevisiae) Homolog (E Coli RecA Homolog), RAD51 Homolog (S. Cerevisiae), RecA E. Coli Homolog Of, Recombination Protein A RecA-Like Protein, HsT16930, HsRad51, HsRAD51, BRCC5, FANCR, MRMV2
    Entrez ID:
    5888
    Related biomarkers:
    Expression
    Mutation
    Fusion
    8ms
    Bleomycin induces senescence and repression of DNA repair via downregulation of Rad51. (PubMed, Mol Med)
    Our works suggest that the inhibition of Rad51 plays a pivotal role in bleomycin-induced AECs senescence and lung injury, offering potential strategies to alleviate the pulmonary toxicity of bleomycin.
    Journal
    |
    RAD51 (RAD51 Homolog A) • E2F1 (E2F transcription factor 1)
    |
    RAD51 overexpression
    |
    bleomycin
    9ms
    Long non-coding RNA RAD51-AS1 promotes the tumorigenesis of ovarian cancer by elevating EIF5A2 expression. (PubMed, J Cancer Res Clin Oncol)
    RAD51-AS1 promoted OvCA progression by the regulation of the miR-140-3p/EIF5A2 axis, which illustrated the potential therapeutic target for OvCA.
    Journal
    |
    RAD51 (RAD51 Homolog A) • EIF5A2 (Eukaryotic Translation Initiation Factor 5A2) • MIR140 (MicroRNA 140)
    |
    RAD51 overexpression
    11ms
    Targeting NEAT1 Affects the Sensitivity to PARPi in Serous Ovarian Cancer by Regulating the Homologous Recombination Repair Pathway. (PubMed, J Cancer)
    NEAT1 expression could predict response to chemotherapy for ovarian cancer. NEAT1 knockdown inhibited HR capacity and increased DNA damage caused by Olaparib in serous ovarian cancer cells, making them more sensitive to Olaparib and providing a crucial therapeutic advantage of increasing sensitivity to Olaparib.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • RAD51 (RAD51 Homolog A) • NEAT1 (Nuclear Paraspeckle Assembly Transcript 1) • FOXM1 (Forkhead Box M1) • H2AX (H2A.X Variant Histone)
    |
    BRCA2 mutation • BRCA1 mutation • RAD51 overexpression
    |
    Lynparza (olaparib)
    11ms
    Rad51 and Systemic Inflammatory Indicators as Novel Prognostic Markers in Esophageal Squamous Cell Carcinoma. (PubMed, Technol Cancer Res Treat)
    Our study found a close correlation between elevated Rad51 expression and inflammatory markers. High Rad51 expression, high neutrophil-to-lymphocyte ratio, and low lymphocyte-to-monocyte ratio are associated with lower survival rates. The combined assessment of Rad51 and inflammatory markers can be useful for preoperative assessment and prognostic evaluation in esophageal squamous cell carcinoma patients.
    Journal
    |
    RAD51 (RAD51 Homolog A) • CRP (C-reactive protein)
    |
    High NLR • RAD51 overexpression • Albumin-L
    1year
    The protein phosphatase EYA4 promotes homologous recombination (HR) through dephosphorylation of tyrosine 315 on RAD51. (PubMed, Nucleic Acids Res)
    Depletion of EYA4 decreases single-stranded DNA accumulation following DNA damage and impairs HR, while overexpression of EYA4 in cells promotes dephosphorylation and stabilization of RAD51, and thereby nucleoprotein filament formation. Our data have implications for a pathological version of RAD51 in EYA4-overexpressing cancers.
    Journal
    |
    RAD51 (RAD51 Homolog A)
    |
    ALK rearrangement • RAD51 overexpression
    1year
    Differential impact of cytoplasmic vs. nuclear RAD51 expression on breast cancer progression and patient prognosis. (PubMed, Int J Oncol)
    The current data suggest that differential expression of subcellular RAD51 had a distinct impact on breast cancer progression and patient survival. Specifically, cytoplasmic RAD51 in contrast to nuclear RAD51 was potentially an adverse marker in breast cancer.
    Journal
    |
    RAD51 (RAD51 Homolog A)
    |
    RAD51 overexpression
    1year
    Enhanced Genomic Stability in Monomorphic Post-Transplant Lymphoproliferative Disorders Is Driven By Distinct Mechanisms Stratified By EBV Status (ASH 2023)
    Like HIV associated DLBCL, these results show that PTLD is more genomically stable than IC-DLBCL, and that genomic stability is further enhanced in EBV(+)PTLD which have increased expression of UPS related genes. In contrast, EBV(-)PTLD have increased expression of DNA damage repair genes, including RAD51. In summary, monomorphic DLBCL PTLD tumors have enhanced genomic stability that appears to be mediated by two distinct mechanisms stratified by EBV status.
    Post-transplantation
    |
    MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • EP300 (E1A binding protein p300) • CHEK1 (Checkpoint kinase 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • CCNA2 (Cyclin A2) • PCNA (Proliferating cell nuclear antigen) • DDB2 (Damage Specific DNA Binding Protein 2) • ERCC3 (ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit) • FANCE (FA Complementation Group E) • POLG2 (DNA Polymerase Gamma 2, Accessory Subunit) • FANCB (FA Complementation Group B)
    |
    RAD51 overexpression • ATM expression
    |
    nCounter® PanCancer Pathways Panel
    1year
    RAD51 is a poor prognostic marker and a potential therapeutic target for oral squamous cell carcinoma. (PubMed, Cancer Cell Int)
    RAD51 is a poor prognostic marker for oral squamous cell carcinoma. High RAD51 protein expression associates with resistance to chemotherapy and radiotherapy. Addition of B02 significantly increased the cytotoxicity of cisplatin. These findings suggest that RAD51 protein may function as a treatment target for oral cancer.
    Journal
    |
    RAD51 (RAD51 Homolog A)
    |
    RAD51 overexpression
    |
    cisplatin
    over1year
    miR-4796 enhances the sensitivity of breast cancer cells to ionising radiation by impairing the DNA repair pathway. (PubMed, Breast Cancer)
    The findings here suggest that miR-4796 can enhance radiation-induced cell death by directly targeting multiple DDR components, and repress NHEJ and HR DNA repair pathways. miR-4796 can act as an effective radiation sensitising agent.
    Review • Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • RAD51 (RAD51 Homolog A) • PARP1 (Poly(ADP-Ribose) Polymerase 1)
    |
    ATM overexpression • RAD51 overexpression • ATM expression • miR-128 expression • miR-1287 expression
    over1year
    A tumor immune microenvironment-based model for prediction of everolimus efficacy in premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Preliminary results from MIRACLE trial (ESMO 2023)
    The results also showed that patients whose tumors were non-responsive to EVE (P = 0.00021) or whose PFS was poor (P = 0.0025) were at a higher risk in the model. Conclusions The immune-related gene model consisting of HDC, TNFRSF1A, and RAD51 could potentially predict the efficacy of EVE in premenopausal patients with HR+/HER2− ABC with endocrine resistance, which could help stratify responders to EVE and guide the choice of EVE in clinical practice.
    Clinical • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8) • RAD51 (RAD51 Homolog A) • TNFRSF1A (TNF Receptor Superfamily Member 1A)
    |
    HR positive • HER-2 negative • EGFR positive • RAD51 overexpression
    |
    everolimus
    almost2years
    HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy. (PubMed, Medicina (Kaunas))
    We found no statistically significant differences but detected trends toward improvement in the survival of HPV-positive and RAD51 overexpressing patients unfit for surgical treatment or chemotherapy treated with hyperfractionated radiotherapy. The trends, however, indicate that in a larger group of patients, the effects of these two parameters would likely be statistically significant.
    Journal
    |
    RAD51 (RAD51 Homolog A)
    |
    RAD51 overexpression
    almost2years
    RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma. (PubMed, J Gynecol Oncol)
    High RAD51 expression was significantly associated with worse PFS in HGSC, and post-NAC RAD51 status showed higher association than pre-NAC RAD51 status. Moreover, RAD51 status can be evaluated in a significant proportion of treatment-naïve HGSC samples. As RAD51 status dynamically changes, sequential follow-up of RAD51 status might reflect the biological behavior of HGSCs.
    Journal
    |
    HRD (Homologous Recombination Deficiency) • RAD51 (RAD51 Homolog A)
    |
    HRD • RAD51 overexpression
    2years
    Canine Mammary Tumor Cell Lines Derived from Metastatic Foci Show Increased RAD51 Expression but Diminished Radioresistance via p21 Inhibition. (PubMed, Vet Sci)
    Since irradiation resulted in the suppression of cell cycle progression in CHMp, the expression of p21, a cell cycle regulatory factor, was detected in CHMp after 15 Gy irradiation but not in CHMm. These results indicate that functional expression is more important than the quantitative expression of RAD51 in canine mammary tumor cells in response to DNA damage.
    Preclinical • Journal • Tumor cell • Metastases
    |
    RAD51 (RAD51 Homolog A) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
    |
    RAD51 overexpression
    2years
    Identification of RAD51 foci in cancer-associated circulating cells and their association with treatment outcomes, in patients with high-grade serous ovarian cancer (HGSOC) (ESMO-GC 2023)
    Numbers of cells and RAD51 foci change with treatment; fewer CC/RAD51 foci are associated with improved PFS. Legal entity responsible for the study East and North Herts NHS Trust, Brunel University London.
    Clinical • BRCA Biomarker
    |
    HRD (Homologous Recombination Deficiency) • WT1 (WT1 Transcription Factor) • BRCA (Breast cancer early onset) • MUC16 (Mucin 16, Cell Surface Associated) • RAD51 (RAD51 Homolog A)
    |
    BRCA mutation • RAD51 overexpression
    over2years
    TRIM36 enhances lung adenocarcinoma radiosensitivity and inhibits tumorigenesis through promoting RAD51 ubiquitination and antagonizing hsa-miR-376a-5p. (PubMed, Biochem Biophys Res Commun)
    TRIM36 and RAD1 may serve as prognostic indicators for LUAD. The interactions between TRIM36, RAD1 and hsa-miR-376a-5p can be future therapeutic targets to increase radiation sensitivity in LUAD patients.
    Journal
    |
    RAD51 (RAD51 Homolog A) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit)
    |
    RAD51 overexpression
    over2years
    Design, synthesis and properties of peptide inhibitors based on BRCA1. (PubMed, Bioorg Med Chem Lett)
    BRCA1 and modified peptides were studied by in vitro cell experiments. The results showed that the antitumor activity of 5-TFM-NA-PP was significantly enhanced compared with BRCA1.
    Journal • BRCA Biomarker
    |
    BRCA1 (Breast cancer 1, early onset) • RAD51 (RAD51 Homolog A)
    |
    RAD51 overexpression
    over2years
    RAD51 interacts with minichromosome maintenance protein complex (MCM2–7) providing strong dependency in myeloma (IMW 2022)
    Our data provide initial evidence for the requirement of RAD51 for assembly and/or regulation of replication machinery at the origins of genome replication in MM cells.
    Clinical
    |
    RAD51 (RAD51 Homolog A) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • WRN (WRN RecQ Like Helicase) • FOXM1 (Forkhead Box M1) • PCNA (Proliferating cell nuclear antigen) • E2F1 (E2F transcription factor 1) • MCM2 (Minichromosome maintenance complex component 2) • RPA3 (Replication Protein A3)
    |
    RAD51 overexpression
    over2years
    U2AF1 mutation Connects DNA Damage to the Alternative Splicing of RAD51 in Lung Adenocarcinomas. (PubMed, Clin Exp Pharmacol Physiol)
    Moreover, A549 cells expressing U2AF1-S34F, but not U2AF1-WT, were highly sensitive to treatment even with low dose of RAD51 inhibitor upon ATRi-induced DNA damage. Together, our results suggest that U2AF1-S34F causes mis-splicing of DNA damage repair factors in lung cancer and sensitizes cells to RAD51 inhibition.
    Journal
    |
    RAD51 (RAD51 Homolog A) • U2AF1 (U2 Small Nuclear RNA Auxiliary Factor 1)
    |
    U2AF1 mutation • RAD51 overexpression • U2AF1 S34F
    over2years
    High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer. (PubMed, Breast Cancer Res Treat)
    RAD51 gene expression is associated with aggressive cancer biology, cancer cell proliferation, and poor survival in breast cancer.
    Journal • Tumor Mutational Burden • BRCA Biomarker
    |
    TMB (Tumor Mutational Burden) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • RAD51 (RAD51 Homolog A)
    |
    HRD • RAD51 overexpression
    over2years
    A Pan-Cancer Bioinformatic Analysis of RAD51 Regarding the Values for Diagnosis, Prognosis, and Therapeutic Prediction. (PubMed, Front Oncol)
    A prognostic nomogram was constructed with a high confidence. RAD51 is a clinical valuable biomarker for multiple cancer types, regarding its potential power for diagnosis, prognosis, and therapeutic prediction.
    Journal • Tumor Mutational Burden • Pan tumor
    |
    TMB (Tumor Mutational Burden) • RAD51 (RAD51 Homolog A)
    |
    RAD51 overexpression • RAD51 mutation
    almost3years
    High RAD51 gene expression is associated with aggressive biology and with poor survival in breast cancer (AACR 2022)
    RAD51 expression was significantly associated with worse survival, but did not with treatment-responsive, suggesting its usefulness as prognostic, but not predictive, biomarker.
    Tumor Mutational Burden • BRCA Biomarker • PARP Biomarker
    |
    TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • RAD51 (RAD51 Homolog A) • CD4 (CD4 Molecule)
    |
    BRCA2 mutation • BRCA1 mutation • HRD • HRD + BRCA1 mutation • BRCA1 expression • RAD51 overexpression • RAD51 mutation
    almost3years
    Berberine enhances gemcitabine‑induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway. (PubMed, Oncol Rep)
    Inactivation of the PI3K/Akt pathway by LY294002 or BER enhanced GEM‑induced cytotoxicity and downregulated Rad51 expression, whilst overexpression of constitutively active Akt restored Rad51 expression and cell viability that was previously decreased by BER and GEM. BER additively inhibited tumor growth and Ki67 expression when combined with GEM in vivo. These results suggest that BER can enhance GEM‑induced cytotoxicity in BC by downregulating Rad51 expression through inactivating the PI3K/Akt pathway, which may represent a novel therapeutic target for BC treatment.
    Journal
    |
    RAD51 (RAD51 Homolog A)
    |
    RAD51 overexpression
    |
    gemcitabine • LY294002
    almost3years
    BRCA2 deficiency increases sensitivity of medulloblastoma to Olaparib by inhibiting RAD51-mediated DNA damage repair system. (PubMed, Clin Transl Oncol)
    Knockdown of BRCA2 increases the sensitivity of medulloblastoma cells to Olaparib and strengthens the efficacy of Olaparib in vitro and in vivo. Knockdown of BRCA2 causes DNA damage repair by regulating RAD51-mediated signaling pathway in Daoy cells.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • RAD51 (RAD51 Homolog A) • RAD50 (RAD50 Double Strand Break Repair Protein) • MRE11A (MRE11 homolog, double strand break repair nuclease)
    |
    RAD51 overexpression
    |
    Lynparza (olaparib)
    3years
    Expression Levels of RAD51 Inversely Correlate with Survival of Glioblastoma Patients. (PubMed, Cancers (Basel))
    We identified 24 adult GBM patients treated with maximal safe resection followed by radiation with concurrent and adjuvant temozolomide...Within this uniformly treated GBM population, RAD51, in the homologous recombination pathway, was overexpressed (vs. normal brain) and inversely correlated with OS. High RAD51 expression may be a prognostic biomarker and a therapeutic target in GBM.
    Clinical • Journal
    |
    RAD51 (RAD51 Homolog A)
    |
    RAD51 overexpression
    |
    temozolomide
    3years
    CTBP1 strengthens the cisplatin resistance of gastric cancer cells by upregulating RAD51 expression. (PubMed, Oncol Lett)
    Overexpression of RAD51 in CTBP1 knockdown AGS/DDP and HGC-27/DDP cells rescued the proliferation and alleviated the apoptosis of these cells. Taken together, the results of the present study suggested that CTBP1 may enhance the DDP resistance of gastric cancer cells by activating RAD51 expression, thus providing a potential novel therapy (CTBP1 knockdown) for the clinical treatment of patients with gastric cancer.
    Journal
    |
    RAD51 (RAD51 Homolog A) • CTBP1 (C-Terminal Binding Protein 1)
    |
    RAD51 overexpression
    |
    cisplatin
    over3years
    Homologous recombination, cancer and the 'RAD51 paradox'. (PubMed, NAR Cancer)
    Taken together, these data highlight the fact that RAD51 differs from its HR partners with regard to cancer susceptibility and expose what we call the 'RAD51 paradox'. Here, we catalogue the dysregulations of HR genes in human pathologies, including cancer and Fanconi anaemia or congenital mirror movement syndromes, and we discuss the RAD51 paradox.
    Journal
    |
    RAD51 (RAD51 Homolog A)
    |
    RAD51 overexpression • RAD51 mutation